JP4729475B2 - 皮下投与型ガングリオシド系ワクチン組成物 - Google Patents
皮下投与型ガングリオシド系ワクチン組成物 Download PDFInfo
- Publication number
- JP4729475B2 JP4729475B2 JP2006501455A JP2006501455A JP4729475B2 JP 4729475 B2 JP4729475 B2 JP 4729475B2 JP 2006501455 A JP2006501455 A JP 2006501455A JP 2006501455 A JP2006501455 A JP 2006501455A JP 4729475 B2 JP4729475 B2 JP 4729475B2
- Authority
- JP
- Japan
- Prior art keywords
- vssp
- vaccine composition
- acgm3
- ganglioside
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 39
- 239000000203 mixture Substances 0.000 title claims description 33
- 150000002270 gangliosides Chemical class 0.000 title claims description 23
- 238000007920 subcutaneous administration Methods 0.000 title claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 1
- -1 N-acetyl GM3 ganglioside Chemical class 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Description
−注射部位に抗原の付着層を作って、抗原を系統的な形で解放又は放出する。
−マクロファージによって捕らえられやすい油性の微小液滴を形成させて、抗原が脾臓及びリンパ節に到達するのを助ける。
−免疫応答に関与する細胞を直接又は間接的に活性化する。
−最もよく知られている免疫アジュバントは、フロイントの完全及び不完全アジュバント、Montanide ISA、Ribiアジュバント、Hunter’s TiterMax、アルミニウム塩、Gerbuアジュバント、QS−21などである。
A:1.2mg/mLのN−AcGM3/VSSPを含有する水溶液
B:1.2mg/mLのN−AcGM3/VSSPを含有するW/O乳濁液
図1に、各実験群の腫瘍成長動力学を示す。Mann−Whitney(両側)U検定を使用して、群の対に統計学的有意性があるかどうか、個別に扱った動物の腫瘍植付け後33日目の腫瘍体積値を評価した。
このパラメーターは、MB16と同程度に致死的な腫瘍に対して、ワクチン接種が、免疫感作した動物の寿命を延長する能力を評価するものである。このパラメーターは、未処理動物の生存度と比較した日数で測定される。たとえば、有意性では、Log−Rank検定を使用している。
経過期間は、接種した瞬間から測定した、各動物の腫瘍がはっきりとわかるようになるのにかかる期間を個々に評価するパラメーターである。表3に結果を示す。
第4及び第5群では、アジュバントを含む又は含まない皮下ワクチン接種に対応して、腫瘍退縮のある動物が観察された。第4群の動物では、接種19日目には腫瘍が測定可能であり、事実上35日まで成長がないままであり、陰性であることがわかった。第5群のマウスでは、接種26日目に触診によって腫瘍の存在が示され、29日目に陰性であると報告された。
実験結果は、本発明の対象のワクチン組成物は、PBSで処理した対象群と比べて有意に生存期間及び経過期間を延長すると同時に腫瘍成長速度を減速させたことが示された。
Claims (5)
- VSSPに含まれる1種又は複数のガングリオシドの溶液又は水性分散液を含有し、かつ、免疫アジュバントを含まない、任意の追加の免疫アジュバントなしで皮下投与によって免疫応答を刺激することのできる皮下投与用ワクチン組成物であって、VSSPに含まれる上記ガングリオシドがN−AcGM3及びN−GcGM3から選択される皮下投与用ワクチン組成物。
- VSSPに含まれるガングリオシドがN−AcGM3である、請求項1に記載のワクチン組成物。
- ガングリオシド以外の抗原を含有しない、請求項1に記載のワクチン組成物。
- 特有の免疫成分としてN−AcGM3/VSSP及び/又はN−GcGM3/VSSPを含有する、請求項1又は3に記載のワクチン組成物。
- 特有の成分としてN−AcGM3/VSSPを含有する、請求項4に記載のワクチン組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU47-2003 | 2003-02-27 | ||
CU20030047A CU23257A1 (es) | 2003-02-27 | 2003-02-27 | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
PCT/CU2004/000003 WO2004075811A2 (es) | 2003-02-27 | 2004-02-27 | Composiciones vacunales a base de gangliósidos para administración subcutánea |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006519186A JP2006519186A (ja) | 2006-08-24 |
JP4729475B2 true JP4729475B2 (ja) | 2011-07-20 |
Family
ID=40091613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006501455A Expired - Lifetime JP4729475B2 (ja) | 2003-02-27 | 2004-02-27 | 皮下投与型ガングリオシド系ワクチン組成物 |
Country Status (37)
Country | Link |
---|---|
US (1) | US8591917B2 (ja) |
EP (1) | EP1604683B1 (ja) |
JP (1) | JP4729475B2 (ja) |
KR (1) | KR100703570B1 (ja) |
CN (1) | CN100418576C (ja) |
AR (1) | AR043377A1 (ja) |
AT (1) | ATE353668T1 (ja) |
AU (1) | AU2004216554B2 (ja) |
BR (1) | BRPI0407854B1 (ja) |
CA (1) | CA2535214C (ja) |
CL (1) | CL2004000374A1 (ja) |
CR (1) | CR7965A (ja) |
CU (1) | CU23257A1 (ja) |
CY (1) | CY1106668T1 (ja) |
DE (1) | DE602004004768T2 (ja) |
DK (1) | DK1604683T3 (ja) |
EA (1) | EA008905B1 (ja) |
EC (1) | ECSP055978A (ja) |
EG (1) | EG26446A (ja) |
ES (1) | ES2280948T3 (ja) |
GE (1) | GEP20074120B (ja) |
HK (1) | HK1087630A1 (ja) |
HR (1) | HRP20050763A2 (ja) |
IL (1) | IL170355A (ja) |
LT (1) | LT5351B (ja) |
LV (1) | LV13400B (ja) |
MY (1) | MY139811A (ja) |
NZ (1) | NZ541952A (ja) |
PE (1) | PE20040955A1 (ja) |
PT (1) | PT1604683E (ja) |
RS (1) | RS20050664A (ja) |
SI (1) | SI1604683T1 (ja) |
TN (1) | TNSN05209A1 (ja) |
TW (1) | TWI344372B (ja) |
UA (1) | UA80859C2 (ja) |
UY (1) | UY28207A1 (ja) |
WO (1) | WO2004075811A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
CU20170173A7 (es) | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0853366A (ja) * | 1993-12-29 | 1996-02-27 | Centro Immunologia Molecular | N−グリコリル化ガングリオシドに対する免疫応答を誘発させるワクチン組成物および癌処置におけるその使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
EP1293212A1 (en) * | 2001-08-21 | 2003-03-19 | National Research Council Of Canada | Anti cancer vaccine comprising whole cancer cells with modified sialic acid |
-
2003
- 2003-02-27 CU CU20030047A patent/CU23257A1/es unknown
-
2004
- 2004-02-24 AR ARP040100571A patent/AR043377A1/es not_active Application Discontinuation
- 2004-02-24 PE PE2004000186A patent/PE20040955A1/es not_active Application Discontinuation
- 2004-02-25 TW TW093104808A patent/TWI344372B/zh not_active IP Right Cessation
- 2004-02-26 CL CL200400374A patent/CL2004000374A1/es unknown
- 2004-02-26 MY MYPI20040641A patent/MY139811A/en unknown
- 2004-02-27 AT AT04715239T patent/ATE353668T1/de active
- 2004-02-27 EP EP04715239A patent/EP1604683B1/en not_active Expired - Lifetime
- 2004-02-27 UY UY28207A patent/UY28207A1/es unknown
- 2004-02-27 CA CA2535214A patent/CA2535214C/en not_active Expired - Lifetime
- 2004-02-27 DE DE602004004768T patent/DE602004004768T2/de not_active Expired - Lifetime
- 2004-02-27 EA EA200501367A patent/EA008905B1/ru not_active IP Right Cessation
- 2004-02-27 KR KR1020057015531A patent/KR100703570B1/ko active IP Right Grant
- 2004-02-27 AU AU2004216554A patent/AU2004216554B2/en not_active Expired
- 2004-02-27 PT PT04715239T patent/PT1604683E/pt unknown
- 2004-02-27 GE GEAP20048952A patent/GEP20074120B/en unknown
- 2004-02-27 US US10/547,164 patent/US8591917B2/en active Active
- 2004-02-27 NZ NZ541952A patent/NZ541952A/en not_active IP Right Cessation
- 2004-02-27 WO PCT/CU2004/000003 patent/WO2004075811A2/es active IP Right Grant
- 2004-02-27 SI SI200430262T patent/SI1604683T1/sl unknown
- 2004-02-27 UA UAA200508381A patent/UA80859C2/xx unknown
- 2004-02-27 JP JP2006501455A patent/JP4729475B2/ja not_active Expired - Lifetime
- 2004-02-27 RS YUP-2005/0664A patent/RS20050664A/sr unknown
- 2004-02-27 DK DK04715239T patent/DK1604683T3/da active
- 2004-02-27 ES ES04715239T patent/ES2280948T3/es not_active Expired - Lifetime
- 2004-02-27 BR BRPI0407854-3A patent/BRPI0407854B1/pt not_active IP Right Cessation
- 2004-02-27 CN CNB2004800052015A patent/CN100418576C/zh not_active Expired - Lifetime
-
2005
- 2005-08-18 IL IL170355A patent/IL170355A/en not_active IP Right Cessation
- 2005-08-20 EG EGPCTNA2005000479A patent/EG26446A/en active
- 2005-08-24 EC EC2005005978A patent/ECSP055978A/es unknown
- 2005-08-26 TN TNP2005000209A patent/TNSN05209A1/en unknown
- 2005-08-26 CR CR7965A patent/CR7965A/es unknown
- 2005-08-29 LV LVP-05-110A patent/LV13400B/en unknown
- 2005-09-02 HR HR20050763A patent/HRP20050763A2/hr not_active Application Discontinuation
- 2005-09-21 LT LT2005087A patent/LT5351B/lt not_active IP Right Cessation
-
2006
- 2006-07-14 HK HK06107889.3A patent/HK1087630A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 CY CY20071100556T patent/CY1106668T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0853366A (ja) * | 1993-12-29 | 1996-02-27 | Centro Immunologia Molecular | N−グリコリル化ガングリオシドに対する免疫応答を誘発させるワクチン組成物および癌処置におけるその使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Silva et al. | Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses | |
Tamayo et al. | Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | |
JP4509554B2 (ja) | アルミニウムアジュバントおよびヒスチジンを含むワクチン | |
JP3814290B2 (ja) | 抗原用のアジュバントおよびその製法ならびに用途 | |
TW200911274A (en) | Alpha-galatosyl ceramide analogs and their use as immunotherapies | |
JP6796146B2 (ja) | 水酸化アルミニウムゲル−塩化ナトリウム複合免疫学的アジュバント、並びにその調製方法及びその使用 | |
JP2015038130A (ja) | 結核のワクチンおよびその使用方法 | |
JPH09511737A (ja) | 免疫治療剤とその使用 | |
JP2005528373A (ja) | 免疫プロトコルにFlt3リガンドを用いる方法 | |
CA2839811A1 (en) | Materials and methods for modulating immune responses | |
JP4729475B2 (ja) | 皮下投与型ガングリオシド系ワクチン組成物 | |
EP3392291B1 (en) | Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene | |
JP2016532712A (ja) | 薬物中毒に対するワクチン組成物 | |
JPS6236501B2 (ja) | ||
CA2255867C (en) | Chitosan induced immunopotentiation | |
Heath et al. | Shaping Modern Vaccines: Adjuvant Systems Tyrosine Using (MCT®) MicroCrystalline | |
Alving et al. | Design and selection of vaccine adjuvants: principles and practice | |
JP4217418B2 (ja) | キトサン誘導性免疫強化 | |
RU2360699C2 (ru) | Композиции менингококковых вакцин с адъювантами | |
AU771525B2 (en) | Chitosan induced immunopotentiation | |
Baogang et al. | Fixed-tumor vaccine: a practical formulation with cytokine-microspheres for protective and therapeutic antitumor immunity | |
AU2012272607A1 (en) | Materials and methods for modulating immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100521 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110412 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4729475 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |